In a clinical trial involving in vivo administration of fezakinumab to patients with moderate to severe AD, the IL-22 high-expression group showed much stronger improvement in transcriptomics mean values compared to the IL-22 high-expression placebo group and the IL-22 low-expression group (138). The gene discussed is IL22; the disease is Alzheimer disease.